J Med Microbiol Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schaumann, R.
Right arrow Articles by Rodloff, A. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schaumann, R.
Right arrow Articles by Rodloff, A. C
Agricola
Right arrow Articles by Schaumann, R.
Right arrow Articles by Rodloff, A. C
J Med Microbiol 54 (2005), 749-753; DOI: 10.1099/jmm.0.45994-0
© 2005 Society for General Microbiology
ISSN 0022-2615

Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures

Reiner Schaumann1, Ellie JC Goldstein2, Jochen Forberg3 and Arne C Rodloff1

1Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Leipzig, Germany 2R. M. Alden Research Laboratories, Santa Monica, CA 90404, USA 3Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany

Correspondence Reiner Schaumann schaur{at}medizin.uni-leipzig.de

Received December 22, 2004
Accepted May 23, 2005

The objective of this study was to determine the pharmacodynamic (PD) activity of moxifloxacin against four selected Bacteroides fragilis strains (three strains with low MICs and one strain with a high MIC) and two Escherichia coli strains (one strain with a low MIC and one strain with a high MIC) in a pharmacokinetic (PK) in vitro model in pure cultures as well as in mixed cultures. PK/PD assays of moxifloxacin were carried out with an initial maximum concentration of 4.0 mg l–1 and a half-life of 13 h. The E. coli strain with the low MIC was rapidly killed in both pure and mixed cultures in the in vitro PK/PD model, while the E. coli strain with the high MIC was not killed. None of the B. fragilis strains were rapidly killed in pure or mixed cultures. The bacterial numbers of the B. fragilis strains with low MICs were reduced by about one to two logs after 12 h in pure cultures. The presence of an E. coli strain with a low or a high MIC in the mixed culture reduced this effect even further.


Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic.




This article has been cited by other articles:


Home page
J Med MicrobiolHome page
K. Valeria dos Santos, C. G. Diniz, S. C. Coutinho, A. C. M. Apolonio, L. Geralda de Sousa-Gaia, J. R. Nicoli, L. d. M. Farias, and M. A. Roque de Carvalho
In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures
J. Med. Microbiol., June 1, 2007; 56(6): 798 - 802.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
H. Stass, A. D. Rink, H. Delesen, D. Kubitza, and K.-H. Vestweber
Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis
J. Antimicrob. Chemother., September 1, 2006; 58(3): 693 - 696.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2005 Society for General Microbiology.